Protalix BioTherapeutics Inc (id:185 PLX)
1.69 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 6:15:51 PM)
Exchange closed, opens in 1 day 15 hours
About Protalix BioTherapeutics Inc
Market Capitalization 103.70M
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
| Headquarters (address) |
Science Park Karmiel 2161401 NJ Israel |
| Phone | 972 4 902 8100 |
| Website | https://www.protalix.com |
| Employees | 208 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | PLX |
| Exchange | New York Stock Exchange |
| Currency | USD |
| 52 week range | 0.820 - 1.90 |
| Market Capitalization | 103.70M |
| P/E trailing | 13.00 |
| P/E forward | 2.27 |
| Price/Sale | 2.73 |
| Price/Book | 3.62 |
| Beta | 0.672 |
| EPS | -0.230 |
| EPS Israel (ID:92, base:52) | -0.441 |